Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-05-28 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
上海泓博智源医药股份有限公司关于2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告
Transaction in Own Shares Classification · 90% confidence The document is a detailed Chinese "临时公告" disclosing the vesting results of the first tranche of a 2024 restricted stock incentive plan, the number of shares to be vested/listed, participant details, board resolutions, repurchase and issuance arrangements, legal opinions, etc. It is not an annual or quarterly report, not an earnings release, and not a vote result. Instead, it involves the company disposing of (issuing) its own repurchased shares to employees under an equity incentive plan. Under FinancialReports taxonomy, this falls under Transaction in Own Shares (POS) – reporting the company’s issuance of its own shares.
2026-05-28 Chinese
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedures and legality of the 2025 Annual General Meeting (AGM) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM. The document does not contain financial statements or detailed financial performance data but focuses on the legal compliance of the AGM process and voting outcomes. It is not the AGM materials themselves but a legal opinion related to the AGM. Given the content and purpose, this document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the legality and results of the shareholder meeting and voting.
2026-05-19 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2025 Annual General Meeting Resolution Announcement" from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the shareholder meeting date, voting methods, attendance, and the results of various resolutions voted on during the meeting. It includes voting percentages, approval of board reports, profit distribution plans, appointment of auditors, director remuneration plans, and authorization for share issuance. The document also contains legal opinions confirming the validity of the meeting and voting procedures. There is no detailed financial data or comprehensive report content, but rather the official announcement of the voting results from the AGM. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" rather than the full AGM materials or annual report. The document length is about 4558 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2026-05-19 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告
Regulatory Filings Classification · 85% confidence The document is titled “中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告” and contains a detailed on‐site inspection (governance, internal control, disclosure, fundraising use, etc.) performed by the sponsor (CITIC Securities) for the period 2025. It is a continuous supervision compliance report required by Chinese regulators (SSE/CSRC) and does not present standalone financial statements, nor is it an earnings release, AGM material, or management discussion. It is not the annual or interim report itself, but a regulatory inspection report. Therefore it falls under the fallback “Regulatory Filings” category.
2026-05-18 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导培训情况的报告
Regulatory Filings Classification · 82% confidence The document is a sponsor’s compliance report submitted to the Shenzhen Stock Exchange under self-regulatory guidelines, detailing the 2025 continuous supervision training program. It does not contain financial statements, earnings data, vote results, or any transaction details. It is a regulatory compliance filing and does not fit specialized categories such as Annual/Interim Reports, Earnings Release, or Board changes. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-18 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司持续督导保荐总结报告书
Regulatory Filings Classification · 84% confidence The document is a “保荐总结报告书” (Sponsorship Summary Report) issued by CITIC Securities summarizing its continuous supervision (“持续督导”) work over the IPO listing of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It is not a financial statement (10-K, IR), earnings release, proxy statement, M&A notice, dividend notice, or any other specific event-driven announcement. It is instead a compliance/supervisory report required under Chinese securities regulations, which does not fit any narrowly defined category. Therefore it should be classified as a fallback Regulatory Filing (RNS).
2026-05-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.